Bookmark
Forward
QuickView for Alendronate (compound)
PubChem
| Name: | Alendronate |
|---|---|
| PubChem Compound ID: | 10131134 |
| Description: | A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis. |
| Molecular formula: | C4H12NO7P2- |
| Molecular weight: | 248.088 g/mol |
DrugBank
Identification
| Name: | Alendronate |
|---|---|
| Name (isomeric): | DB00630 |
| Drug Type: | small molecule |
| Description: | A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis. |
| Synonyms: |
Alendronic acid; Acidum Alendronicum [INN-Latin]; Acido Alendronico [INN-Spanish]; Alendronate Sodium; Acide Alendronique [INN-French]
|
| Brand: | Onclast, Arendal, Fosamax Plus D, Alendros, Adronat, Fosamax |
| Brand name mixture: | Fosavance(alendronate sodium + cholecalciferol) |
| Category: | Antihypocalcemic Agents, Bisphosphonates, Bone Density Conservation Agents, Antiresorptives |
| CAS number: | 66376-36-1 |
Pharmacology
| Indication: | For the treatment and prevention of osteoporosis in women and Paget's disease of bone in both men and women. |
|---|---|
| Pharmacology: | Alendronate, a second-generation bisphosphonate is the first member of a group of drugs which strengthens bone. Alendronate is used to reduce hypercalcemia in tumor-induced bone disease, to treat corticosteroid-induced osteoporosis and Paget's disease, and to prevent osteoporosis in postmenopausal women. |
| Mechanism of Action: |
The action of Alendronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Alendronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isopr...
show more » |
| Absorption: | Relative to an intravenous (IV) reference dose, the mean oral bioavailability of alendronate in women was 0.7% for doses ranging from 5 to 40 mg when administered after an overnight fast and two hours before a standardized breakfast. Oral bioavailability of the 10 mg tablet in men (0.59%) was similar to that in women (0.78%) when administered after an overnight fast and 2 hours before breakfast. |
| Protein binding: | 78% |
| Biotransformation: | There is no evidence that alendronate is metabolized in humans or animals. |
| Route of elimination: | Following a single IV dose of [14C]alendronate, approximately 50% of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the feces. |
| Half Life: | >10 years |
| Clearance: | <200 mL/min [A single 10 mg IV dose] |
| Toxicity: | Alendronate can damage the esophagus both by toxicity from the medication itself and by nonspecific irritation secondary to contact between the pill and the esophageal mucosa, similar to other cases of "pill esophagitis." |
| Affected organisms: | Humans and other mammals |
Interactions
| Food interaction: |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug interaction: |
|
Targets
